Patterns of cytomegalovirus reactivation are associated with distinct evolutive profiles of immune reconstitution after allogeneic hematopoietic stem cell transplantation.

T cell-mediated immunity is essential for the control of cytomegalovirus (CMV) infections in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). Our aims were to identify patterns of CMV-specific immune responses associated with multiple or prolonged reactivations. We analyzed findings in 116 recipients during the course of infection or reactivation and latency. CD8(+) T cell responses were determined weekly, using HLA class I tetramers together with extended phenotypic analyses. Our results confirmed that recipients of allo-HSCT from unrelated donors were more susceptible to multiple reactivations and that the donor's CMV serological status influenced the occurrence of prolonged reactivations. We found that a lack of CMV-specific T cells after the first episode of reactivation was associated with multiple subsequent reactivations. In patients with uncontrolled reactivations, CMV-specific T cells of the late differentiation phenotype CD45RA(+)CD27(-)CD28(-) did not develop. Longitudinal evaluation of CD27 and CD45RA expression within the tetramer-positive subset could help identify patients in whom a protective immune response is developing. Evaluation of CMV-specific immune responses during the first episode of reactivation, together with extended phenotypes, could thus improve immune monitoring, especially in recipients at risk of uncontrolled viral reactivation.

[1]  D. Lilleri,et al.  Prospective simultaneous quantification of human cytomegalovirus-specific CD4+ and CD8+ T-cell reconstitution in young recipients of allogeneic hematopoietic stem cell transplants. , 2006, Blood.

[2]  R. V. van Lier,et al.  Human virus‐specific CD8+ T cells: diversity specialists , 2006, Immunological reviews.

[3]  T. Sakurai,et al.  Evaluation of cytomegalovirus‐specific T‐cell reconstitution in patients after various allogeneic haematopoietic stem cell transplantation using interferon‐γ‐enzyme‐linked immunospot and human leucocyte antigen tetramer assays with an immunodominant T‐cell epitope , 2005, British journal of haematology.

[4]  G. Carcelain,et al.  Repertoire, diversity, and differentiation of specific CD8 T cells are associated with immune protection against human cytomegalovirus disease , 2005, The Journal of experimental medicine.

[5]  Antonio Lanzavecchia,et al.  Understanding the generation and function of memory T cell subsets. , 2005, Current opinion in immunology.

[6]  D. Lilleri,et al.  Simultaneous quantification of human cytomegalovirus (HCMV)‐specific CD4+ and CD8+ T cells by a novel method using monocyte‐derived HCMV‐infected immature dendritic cells , 2005, European journal of immunology.

[7]  R. Hetzer,et al.  Protection from cytomegalovirus after transplantation is correlated with immediate early 1–specific CD8 T cells , 2005, The Journal of experimental medicine.

[8]  W. Haq,et al.  Simultaneous reconstitution of multiple cytomegalovirus-specific CD8+ cell populations with divergent functionality in hematopoietic stem-cell transplant recipients. , 2005, The Journal of infectious diseases.

[9]  Victor Appay,et al.  Lessons from the study of T-cell differentiation in persistent human virus infection. , 2004, Seminars in immunology.

[10]  F. Locatelli,et al.  T lymphocytes of recipient origin may contribute to the recovery of specific immune response toward viruses and fungi in children undergoing cord blood transplantation. , 2004, Blood.

[11]  E. Remmerswaal,et al.  The Size and Phenotype of Virus-Specific T Cell Populations Is Determined by Repetitive Antigenic Stimulation and Environmental Cytokines 1 , 2004, The Journal of Immunology.

[12]  D. Olive,et al.  Cytomegalovirus-specific immune recovery following allogeneic HLA-identical sibling transplantation with reduced-intensity preparative regimen , 2004, Bone Marrow Transplantation.

[13]  R. Welsh,et al.  Immunological Memory to Viral Infections1 , 2004 .

[14]  A. Toubert,et al.  Epstein-barr virus (EBV) reactivation in allogeneic stem-cell transplantation: relationship between viral load, EBV-specific T-cell reconstitution and rituximab therapy , 2004, Transplantation.

[15]  H. Einsele,et al.  Donor CMV serologic status and outcome of CMV-seropositive recipients after unrelated donor stem cell transplantation: an EBMT megafile analysis. , 2003, Blood.

[16]  I. Berge,et al.  Human CD8+ T-cell differentiation in response to viruses , 2003, Nature Reviews Immunology.

[17]  J. Madrigal,et al.  Factors affecting reconstitution of the T cell compartment in allogeneic haematopoietic cell transplant recipients , 2003, Bone Marrow Transplantation.

[18]  S. Riddell,et al.  Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: impact of host factors, drug therapy, and subclinical reactivation. , 2003, Blood.

[19]  G. Papanicolaou,et al.  Cytomegalovirus in hematopoietic stem cell transplant recipients: Current status, known challenges, and future strategies. , 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[20]  R. V. van Lier,et al.  Frequencies of Circulating Cytolytic, CD45RA+CD27−, CD8+ T Lymphocytes Depend on Infection with CMV1 , 2003, The Journal of Immunology.

[21]  S. Rowland-Jones,et al.  Cytomegalovirus reactivation following allogeneic stem cell transplantation is associated with the presence of dysfunctional antigen-specific CD8+ T cells. , 2002, Blood.

[22]  L. Verdonck,et al.  Influence of cytomegalovirus seropositivity on outcome after T cell-depleted bone marrow transplantation: contrasting results between recipients of grafts from related and unrelated donors. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  W. Leisenring,et al.  Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. , 2002, Blood.

[24]  Hans-Georg Rammensee,et al.  Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. , 2002, Blood.

[25]  D. Richman,et al.  Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections , 2002, Nature Medicine.

[26]  S. Grace,et al.  Cytomegalovirus-specific cellular immune responses and viremia in recipients of allogeneic stem cell transplants. , 2001, The Journal of infectious diseases.

[27]  C. Tournay,et al.  Tetramer-based quantification of cytomegalovirus (CMV)-specific CD8+ T lymphocytes in T-cell-depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection. , 2001, Blood.

[28]  S. Chevret,et al.  Relationship between HLA alleles and cytomegalovirus infection after allogenic hematopoietic stem cell transplant. , 2001, Blood.

[29]  A. Zander,et al.  Patient cytomegalovirus seropositivity with or without reactivation is the most important prognostic factor for survival and treatment‐related mortality in stem cell transplantation from unrelated donors using pretransplant in vivo T‐cell depletion with anti‐thymocyte globulin , 2001, British journal of haematology.

[30]  C. Craddock,et al.  Direct visualization of cytomegalovirus-specific T-cell reconstitution after allogeneic stem cell transplantation. , 2001, Blood.

[31]  T. Schumacher,et al.  CMV-specific CD8(pos) T lymphocyte differentiation in latent CMV infection. , 2001, Transplantation proceedings.

[32]  C. Craddock,et al.  Cytomegalovirus seropositivity adversely influences outcome after T‐depleted unrelated donor transplant in patients with chronic myeloid leukaemia: the case for tailored graft‐versus‐host disease prophylaxis , 2001, British journal of haematology.

[33]  V. Kuenen-Boumeester,et al.  Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation. , 2000, Blood.

[34]  F. Sallusto,et al.  Two subsets of memory T lymphocytes with distinct homing potentials and effector functions , 1999, Nature.

[35]  C. Sabin,et al.  Longitudinal fluctuations in cytomegalovirus load in bone marrow transplant patients: relationship between peak virus load, donor/recipient serostatus, acute GVHD and CMV disease , 1998, Bone Marrow Transplantation.

[36]  M. Rep,et al.  Phenotypic and Functional Separation of Memory and Effector Human CD8+ T Cells , 1997, The Journal of experimental medicine.

[37]  K. Sullivan,et al.  Infectious morbidity in long‐term survivors of allogeneic marrow transplantation is associated with low CD4 T cell counts , 1997, American journal of hematology.

[38]  S. Riddell,et al.  Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. , 1995, The New England journal of medicine.

[39]  G. Gerna,et al.  Human cytomegalovirus (HCMV) infection in paediatric patients given allogeneic bone allogeneic bone marrow transplantation: role of early antiviral treatment for HCMV antigenaemaia on Patients' outcome , 1994 .

[40]  S. Riddell,et al.  Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. , 1994, Blood.

[41]  S. Riddell,et al.  Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. , 1992, Science.

[42]  S. Riddell,et al.  Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. , 1991, Blood.

[43]  J. Sissons,et al.  Human cytomegalovirus-specific cytotoxic T cells. Relative frequency of stage-specific CTL recognizing the 72-kD immediate early protein and glycoprotein B expressed by recombinant vaccinia viruses , 1988, The Journal of experimental medicine.

[44]  J. Manischewitz,et al.  Cytotoxic t cells in cytomegalovirus infection: HLA-restricted T-lymphocyte and non-T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone-marrow-transplant recipients. , 1982, The New England journal of medicine.

[45]  M. Heemskerk,et al.  Pretransplantation CMV-specific T cells protect recipients of T-cell-depleted grafts against CMV-related complications. , 2006, Blood.

[46]  R. Welsh,et al.  Immunological memory to viral infections. , 2004, Annual review of immunology.

[47]  D. Marks,et al.  Influence of cytomegalovirus (CMV) sero-positivity on CMV infection, lymphocyte recovery and non-CMV infections following T-cell-depleted allogeneic stem cell transplantation: a comparison between two T-cell depletion regimens , 2004, Bone Marrow Transplantation.

[48]  M. Maris,et al.  The transplantation of hematopoietic stem cells after non-myeloablative conditioning , 2003, Immunologic research.

[49]  Susan M. Kaech,et al.  Effector and memory T-cell differentiation: implications for vaccine development. Nat Rev Immunol. , 2002 .

[50]  G. Gerna,et al.  Human cytomegalovirus (HCMV) infection in paediatric patients given allogeneic bone marrow transplantation: role of early antiviral treatment for HCMV antigenaemia on patients' outcome. , 1994, British journal of haematology.